Global bioethical challenges of medicalising psychedelics
Journal of Psychedelic Studies September 17, 2021 DOI: 10.1556/2054.2021.00188 via OpenAlex
Summary
AI-generated from the abstractThe re-medicalisation of psychedelics risks turning their ecological sources, cultural contexts, and therapeutic experiences into exploitable resources, endangering ecosystems, appropriating traditional knowledge, and reducing therapeutic effects. Applying Martin Heidegger's critique of modern technology and Fredrik Svenaeus' extension reveals these normative issues. Preserving non-reductionist, non-instrumentalising traditional understandings of psychedelic compounds is essential to mitigate these consequences. Bioethicists have remained silent on this topic, and more discussion is needed to address these global challenges for the psychedelic renaissance.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Bioethics Normative Reductionism Epistemology Sociology |
| Citations | 13 |
| Key finding | The re-medicalisation of psychedelics risks turning ecological sources, cultural contexts, and experiences into exploitable resources, endangering ecosystems, appropriating traditional knowledge, and reducing therapeutic effects, and preserving non-reductionist traditional understandings is essential to mitigate these consequences. |
Abstract
Abstract Psychedelic-assisted psychotherapy is an emerging psychiatric treatment that is attracting significant scientific, medical, and public attention. Whilst preliminary results from empirical studies are promising, the medical use of these compounds is highly controversial. Surprisingly, and despite the current controversies caused by the re-medicalisation of psychedelics, bioethicists have remained mysteriously silent. This paper aims to stimulate further bioethical reflection regarding the re-medicalisation of psychedelics. The current paper aims to do this by applying a normative phenomenological lens of analysis. Namely, this paper applies Martin Heidegger's critique of modern technology, and Fredrik Svenaeus' extension of this critique, to the re-medicalisation of psychedelics. I argue that when this critique of modern technology is applied several normative issues become apparent. Specifically, it becomes apparent that the re-medicalisation of psychedelics risks turning the ecological sources, cultural contexts, and experiences induced by psychedelics into resources to be exploited for human goals; all of which risks endangering ecosystems, appropriating traditional knowledge, and reducing the therapeutic effects of psychedelic-assisted psychotherapy. Furthermore, I suggest that preserving non-reductionist, non-instrumentalising traditional ways of understanding psychedelic compounds is essential in mitigating these consequences. More discussion by bioethicists is necessary as these consequences represent important global challenges for the psychedelic renaissance that require immediate addressing.